Race and survival of men after docetaxel-based treatment for mCRPC

Posted on December 27, 2018 by Sitemaster

A new paper in the Journal of Clinical Oncology has just reported that the overall survival (OS) of black and white men diagnosed with metastatic castration-resistant prostate cancer (mCRPC) seems to be near to identical after treatment with docetaxel or a docetaxel-containing regimen. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , | Leave a comment »

Results of PLATO trial published in JCO

Posted on September 25, 2018 by Sitemaster

The results of the PLATO trial have just been published in the Journal of Clinical Oncology (JCO). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | Leave a comment »

What to do first for men with mCRPC

Posted on February 5, 2018 by Sitemaster

The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , | 4 Comments »

Ac-225-PSMA-617 in mCRPC: an update

Posted on January 14, 2018 by Sitemaster

We now have some details from clinical trials of the radiopharmaceutical actinium-225-PSMA-617 (Ac-225-PSMA-617) in very advanced prostate cancer patients. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , | 3 Comments »

BAT + enzalutamide: data from the RESTORE study

Posted on January 3, 2018 by Sitemaster

Just over a year ago we wrote up a commentary on this web site entitled, “Can bipolar cycling of testosterone really cure prostate cancer?” It dealt with what is known as “bipolar androgen therapy” or BAT and referred to a Phase II clinical trial known as the RESTORE study. … READ MORE …

Filed under: Living with Prostate Cancer, Management | Tagged: , , , , , , , | Leave a comment »

Does Lu-177-PSMA-617 increase survival?

Posted on October 17, 2017 by Sitemaster

We have enthusiastically reported the encouraging outcomes of the early clinical trials of the radiopharmaceutical Lu-177-PSMA, most recently at this link. Based on reduction in PSA levels, it performs well. But medicines have no real benefit if all they do is treat PSA. We want medicines that increase survival. … READ MORE …

Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , | 8 Comments »

Do men with mCRPC need to stay on ADT along with their abiraterone acetate?

Posted on October 16, 2017 by Sitemaster

On and off over the past few years your sitemaster has raised the question of whether there is any real clinical benefit to maintaining men on standard androgen deprivation therapy (ADT) once they become castrate resistant and are switched to treatment with newer drugs like abiraterone acetate (Zytiga) or enzalutamide (Xtandi). … READ MORE …

Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: , , , , , , , , | Leave a comment »

Next Page »